High resolution HLA genotyping with third generation sequencing technology—A multicentre study
HLA · 2024-08 · 104 (2)
DOI: 10.1111/tan.15632 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift HLA, online erschienen am 12.08.2024. Verfasst von Stéphane Buhler und 7 weiteren Autor:innen. Beteiligte Einrichtung: Transplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva University Hospitals, Gene…. Hauptthemen laut MEDLINE: Histocompatibility Testing, High-Throughput Nucleotide Sequencing, HLA Antigens. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Molecular HLA typing techniques are currently undergoing a rapid evolution. While real‐time PCR is established as the standard method in tissue typing laboratories regarding allocation of solid organs, next generation sequencing (NGS) for high‐resolution HLA typing is becoming indispensable but is not yet suitable for deceased donors. By contrast, high‐resolution typing is essential for stem cell transplantation and is increasingly required for questions relating to various disease associations. In this multicentre clinical study, the TGS technique using nanopore sequencing is investigated applying NanoTYPE™ kit and NanoTYPER™ software (Omixon Biocomputing Ltd., Budapest, Hungary) regarding the concordance of the results with NGS and its practicability in diagnostic laboratories. The results of 381 samples show a concordance of 99.58% for 11 HLA loci, HLA‐A , ‐B , ‐C , ‐DRB1 , ‐DRB3 , ‐DRB4 , ‐DRB5 , ‐DQA1 , ‐DQB1 , ‐DPA1 and ‐DPB1 . The quality control (QC) data shows a very high quality of the sequencing performed in each laboratory, 34,926 (97.15%) QC values were returned as ‘passed’, 862 (2.4%) as ‘inspect’ and 162 (0.45%) as ‘failed’. We show that an ‘inspect’ or ‘failed’ QC warning does not automatically lead to incorrect HLA typing. The advantages of nanopore sequencing are speed, flexibility, reusability of the flow cells and easy implementation in the laboratory. There are challenges, such as exon coverage and the handling of large amounts of data. Finally, nanopore sequencing presents potential for applications in basic research within the field of epigenetics and genomics and holds significance for clinical concerns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Transplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.
- Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- Laboratory for Transplantation Immunology, University Hospital Leipzig, Leipzig, Germany.
ORCID-Profile: Stéphane Buhler, Kirstine Kløve-Mogensen, Claudia Lehmann
Zitieren
APA
Buhler, S., Nørgaard, M., Steffensen, R., Kløve-Mogensen, K., Møller, B. K., Grossmann, R., Ferrari-Lacraz, S., & Lehmann, C. (2024). High resolution HLA genotyping with third generation sequencing technology—A multicentre study. HLA, 104(2). https://doi.org/10.1111/tan.15632
Vancouver
Buhler S, Nørgaard M, Steffensen R, Kløve-Mogensen K, Møller BK, Grossmann R, et al. High resolution HLA genotyping with third generation sequencing technology—A multicentre study. HLA. 2024;104(2). doi:10.1111/tan.15632
BibTeX
@article{Buhler2024,
author = {Buhler, Stéphane and Nørgaard, Maja and Steffensen, Rudi and Kløve-Mogensen, Kirstine and Møller, Bjarne Kuno and Grossmann, Rebecca and Ferrari-Lacraz, Sylvie and Lehmann, Claudia},
title = {High resolution HLA genotyping with third generation sequencing technology—A multicentre study},
journal = {HLA},
year = {2024},
volume = {104},
number = {2},
doi = {10.1111/tan.15632}
}
EUVIMED